Valuation : Kamada Ltd.

Market Cap 1.41B 141B 465M 400M 378M 343M 642M 44.33B 649M 4.5B 1.73B 22.55B 1.74B 1.71B 71.72B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.41B 141B 465M 400M 378M 343M 642M 44.33B 649M 4.5B 1.73B 22.55B 1.74B 1.71B 71.72B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.1x
Free-Float
54.48%
Yield 2026 *
-
Yield 2027 * -
1 day-1.53%
1 week-3.35%
Current month+0.08%
1 month+14.47%
3 months+14.26%
6 months-9.49%
Current year+8.50%
1 week 2,443
Extreme 2443
2,546
1 month 2,013
Extreme 2013
2,578
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 58 2015-06-30
Director of Finance/CFO 56 2017-12-30
Chief Operating Officer 54 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Exercice

VP Quality

6,937 0.0120%
9/2/26 Exercice

Founder

107,166 0.1857%
8/26/26 Exercice

VP Quality

68,328 0.1184%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-3.35%+1.74%+19.03% 474M
-1.78%-6.90%+42.54%-4.51% 80.65B
-1.00%-2.50%-19.26%-37.42% 59.12B
+0.74%-9.41%+458.32%+26.92% 54.14B
-2.00%-5.20%-11.09%+27.83% 50.1B
-1.42%-8.53%-3.54%+144.43% 45.33B
+2.23%-3.25%+50.02%-16.82% 31.14B
-2.17%-4.31%+44.02%+92.69% 25.54B
-3.92%-7.32%-6.49%+166.90% 21.8B
-0.99%-3.56%+58.64%+102.21% 16.06B
Average -1.31%-3.59%+61.49%+52.13% 38.44B
Weighted average by Cap. -1.26%-3.84%+77.72%+36.31%

Financials

2026 *2027 *
Net sales 606M 60.59B 199M 171M 162M 147M 275M 18.99B 278M 1.93B 741M 9.66B 747M 731M 30.72B 673M 67.32B 221M 190M 180M 163M 306M 21.1B 309M 2.14B 824M 10.73B 830M 812M 34.14B
Net income 84.8M 8.48B 27.85M 23.99M 22.64M 20.59M 38.49M 2.66B 38.9M 270M 104M 1.35B 105M 102M 4.3B 104M 10.41B 34.19M 29.45M 27.8M 25.28M 47.26M 3.26B 47.76M 331M 127M 1.66B 128M 126M 5.28B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
26-09-10 ILA 2,452.00 -1.53% 69,336
26-09-09 ILA 2,490.00 +0.08% 130,011
26-09-08 ILA 2,488.00 -0.12% 317,225
26-09-07 ILA 2,491.00 0.00% 57,863
26-09-04 ILA 2,491.00 +0.44% 90,400
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!